14th May 2015 08:35
LONDON (Alliance News) - Silence Therapeutics PLC said Thursday that positive results from its Phase 2a trial of Atu027 in pancreatic cancer has encouraged it to focus its existing resources on pursuing pancreatic cancer as its main focus, deferring plans for a potential head and neck cancer study.
The company believes that the implication of higher and more frequent dosing warrants investigation ahead of a full Phase II study in pancreatic cancer. It said that once a dosing regimen has been optimised in pancreatic cancer, it can address other metastatic cancers like head and neck.
"An indication in head and neck cancer remains a consideration for the future, but our priority is to progress our drug through definitive clinical trials in pancreatic cancer patients," said Chief Executive Officer Ali Mortazavi in a statement.
It will provide a further statistical analysis of its Phase 2a study with its annual general meeting statement, which it will release June 1.
Shares in Silence Therapeutics are trading up 2.8% at 313.52 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
SLN.L